Inotek Pharmaceuticals Corp Share Price Nasdaq
Equities
US45780V1026
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
Sales 2024 * | 29.54M 0 2.46B | Sales 2025 * | 186M 0 15.49B | Capitalization | 1.99B 0 166B |
---|---|---|---|---|---|
Net income 2024 * | -262M - -21.85B | Net income 2025 * | -217M - -18.1B | EV / Sales 2024 * | 61.8 x |
Net cash position 2024 * | 163M 0 13.63B | Net cash position 2025 * | 59.29M 0 4.94B | EV / Sales 2025 * | 10.4 x |
P/E ratio 2024 * |
-8.27
x | P/E ratio 2025 * |
-11.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.43% |
Latest transcript on Inotek Pharmaceuticals Corp
Managers | Title | Age | Since |
---|---|---|---|
Gaurav D. Shah
CEO | Chief Executive Officer | 49 | 04/18/04 |
Kinnari Patel
PSD | President | 46 | 04/18/04 |
Chief Tech/Sci/R&D Officer | 60 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pedro Granadillo
BRD | Director/Board Member | 77 | 04/18/04 |
Carsten Boess
BRD | Director/Board Member | 57 | 01/16/01 |
David Southwell
BRD | Director/Board Member | 63 | 01/14/01 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |